LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

LLY

898.5

-1.78%↓

JNJ

239.25

-0.3%↓

ABBV

211.26

+2.28%↑

NVS

149.54

-0.8%↓

MRK

118.94

-0.3%↓

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Cerrado

1.24 -4.62

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.23

Máximo

1.31

Métricas clave
By Trading Economics
Ingresos	2.7M -24M
BPA	-0.354
Empleados	49
EBITDA	-5.3M -28M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+103.82% upside

Dividendos
By Dow Jones
Próximas Ganancias	7 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-1.2M 80M
Apertura anterior	5.86
Cierre anterior	1.24

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

26 mar 2026, 23:43 UTC

Charlas de Mercado

Nikkei May Decline Amid Uncertainty Over Iran Peace Talks -- Market Talk

26 mar 2026, 23:36 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Rises Amid Signs of Easing Middle East Tensions -- Market Talk

26 mar 2026, 23:35 UTC

Adquisiciones, fusiones, absorciones

Pernod Ricard: Confirms Discussions With Brown-Forman

26 mar 2026, 23:29 UTC

Ganancias

Haier Smart Home: Company to Finance Share Buybacks Via Internal Funds >600690.SH

26 mar 2026, 23:28 UTC

Ganancias

Haier Smart Home Plans A Share Buybacks of CNY3.0B-CNY6.0B >600690.SH

26 mar 2026, 23:28 UTC

Ganancias

Haier Smart Home Plans to Increase Payout Ratio to 60% for 2027, 2028 >600690.SH

26 mar 2026, 23:28 UTC

Ganancias

Haier Smart Home Plans Cash Dividend Payout Ratio of Up to 58% for 2026 >600690.SH

26 mar 2026, 23:27 UTC

Ganancias

Haier Smart Home 2025 Net CNY19.55B Vs. Net CNY18.73B >600690.SH

26 mar 2026, 23:27 UTC

Ganancias

Haier Smart Home 2025 Rev CNY302.33B Vs. CNY286.01B >600690.SH

26 mar 2026, 23:08 UTC

Charlas de Mercado

Infratil's Investor Day Addresses Data-Center Issues -- Market Talk

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Pernod Ricard in Talks to Combine With Jack Daniel's Maker Brown-Forman -- WSJ

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Families Behind Pernod, Brown-Forman Would Each Likely Retain Significant Stakes, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Pernod, Brown-Forman Discussing Mostly Stock Deal, Source Says -- WSJ

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Pernod-Brown-Forman Deal Announcement Could Be Weeks Away, Sources Say -- WSJ

26 mar 2026, 23:04 UTC

Adquisiciones, fusiones, absorciones

Pernod in Deal Talks With Brown-Forman -- WSJ

26 mar 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Brown-Forman: No Agreement Has Been Reached as to Terms of Any Possible Pernod Ricard Transaction

26 mar 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Brown-Forman: Synergies From Contemplated Pernod Ricard Combination Expected to Be Significant

26 mar 2026, 22:26 UTC

Ganancias

Jiangxi Copper 2025 Rev CNY544.62B Vs. CNY516.61B >0358.HK

26 mar 2026, 22:26 UTC

Ganancias

Jiangxi Copper 2025 Net CNY7.13B Vs. Net CNY6.96B >0358.HK

26 mar 2026, 22:26 UTC

Ganancias

Jiangxi Copper Higher Demand For Products Supported Results>0358.HK

26 mar 2026, 22:08 UTC

Ganancias

Air China 2025 Loss CNY1.79B Vs. Loss CNY232.56M >0753.HK

26 mar 2026, 22:08 UTC

Ganancias

Air China Impairment Loss on Goodwill Weighed on Results>0753.HK

26 mar 2026, 22:08 UTC

Ganancias

Air China 2025 Rev CNY171.48B Vs. CNY166.70B >0753.HK

26 mar 2026, 22:07 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Global Energy Roundup: Market Talk

26 mar 2026, 22:07 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Open-Pit Gold Miners Most Exposed to High Fuel Prices -- Market Talk

26 mar 2026, 22:00 UTC

Ganancias

Tsingtao Brewery 2025 Net CNY4.59B Vs. Net CNY4.34B >0168.HK

26 mar 2026, 22:00 UTC

Ganancias

Tsingtao Brewery: Higher Volume Sales of Beer Supported Results>0168.HK

26 mar 2026, 22:00 UTC

Ganancias

Tsingtao Brewery 2025 Rev CNY32.47B Vs. CNY32.14B >0168.HK

26 mar 2026, 21:39 UTC

Adquisiciones, fusiones, absorciones

BlueScope: Sees Early Indications of Strong Interest in Site Adjacent Western Port

26 mar 2026, 21:38 UTC

Adquisiciones, fusiones, absorciones

BlueScope: Has Begun Expression of Interest Process For 65-Hectare Site Adjacent Western Port

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

103.82% repunte

Estimación a 12 Meses

Media 2.67 USD 103.82%

Máximo 3 USD

Mínimo 2 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.